Please provide your email address to receive an email when new articles are posted on . Sulcus placement is more technically difficult but preserves endothelial cells. Consider factors such as eye ...
The multi‐site VITA trial, a prospective pilot study designed to assess the safety and effectiveness of Avisi Technologies' investigational VisiPlate® device, enrolled and treated 15 subjects (mean ...
Trabeculectomy as a first-line procedure to treat glaucoma is more cost-effective than tube shunt surgery for people with elevated intraocular pressure (IOP), but tube shunt surgery may be the better ...
REDWOOD CITY, Calif., Dec. 2, 2025 /PRNewswire/ -- Avisi Technologies, Inc., an ophthalmic medical device company advancing novel, sight-saving technologies, announces the first patient in the ...
You may have heard the term “glaucoma” before, but what is it really, and how do you know if you have it? Glaucoma is an eye disease in which the optic nerve is damaged over time due to elevated ...
The risk for endophthalmitis in patients with glaucoma who undergo drainage procedures appears to persist for at least 5 years after the initial operation, a new research showed. The findings, from ...
Company’s first-of-its-kind titratable glaucoma therapy system aims to optimize intraocular pressure (IOP) reduction for patients with moderate to severe glaucoma Results demonstrate significant IOP ...
Glaucoma, a vision impairment caused by a buildup of pressure in the eye, affects more than 2 million Americans, with millions more at risk. Surgical treatments for hard-to-control cases include the ...
In Bihar, awareness about glaucoma is gradually increasing, and many eye hospitals now provide advanced treatment solutions based on the stage and type of the disease.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results